The leukemogenic BCR-ABL fusion protein activates multiple signal transduction pathways which, in turn, may affect the expression of genes implicated in the pathogenesis of CML [14]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.